首页> 外文期刊>Modern Pathology >Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification
【24h】

Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification

机译:表皮生长因子受体在肛管鳞状细胞癌中的表达与基因扩增无关

获取原文
       

摘要

Immunohistochemical detection of expression of the epidermal growth factor receptor (EGFR) has been utilized to identify eligible patients with solid malignant tumors, including colorectal adenocarcinoma, for monoclonal antibody therapy (eg, cetuximab). The EGFR status in squamous cell carcinoma of the anal canal, an uncommon malignancy traditionally treated with chemoradiation, has not been well investigated. In this study, 38 primary squamous cell carcinomas of the anal canal were immunohistochemically examined for EGFR expression and analyzed by fluorescence in situ hybridization (FISH) for EGFR gene copy numbers. The results showed a variable degree of EGFR expression in 21 (55%) tumors, among which 13 (62%) cases exhibited a 2+ to 3+ staining pattern according to the Dako EGFR phamDx interpretation guide. There were no significant differences among tumors stratified by stage, degree of keratinization, or tissue block storage times. FISH analysis showed that none of the 34 cases with interpretable results had EGFR gene amplification. Increased gene copy numbers due to polysomy 7 were seen in seven of 18 (39%) cases that expressed EGFR protein and four of 16 (25%) cases that did not (P=0.3876). Ten (56%) tumors with positive EGFR staining showed a balanced disomy 7 pattern and one case with monosomy 7 exhibited strong EGFR expression (3+). These results demonstrate that EGFR is overexpressed in more than one-half of the squamous cell carcinomas of the anal canal through mechanisms other than gene amplification. These observations may have important therapeutic implications since EGFR-based targeted therapies have shown promise for other malignant neoplasms.
机译:免疫组织化学检测表皮生长因子受体(EGFR)的表达已被用于鉴定具有实体恶性肿瘤(包括结直肠腺癌)的合格患者,以进行单克隆抗体治疗(例如西妥昔单抗)。肛管鳞状细胞癌中的EGFR状态是一种传统上用化学放射治疗的罕见恶性肿瘤,目前尚未得到很好的研究。在这项研究中,对38例原发性肛管鳞状细胞癌的EGFR表达进行了免疫组织化学检查,并通过荧光原位杂交(FISH)分析了EGFR基因的拷贝数。结果显示,根据Dako EGFR phamDx解释指南,在21个(55%)的肿瘤中EGFR表达的程度不同,其中13(62%)的患者呈现2+至3+的染色模式。按阶段,角化程度或组织块储存时间分层的肿瘤之间无显着差异。 FISH分析显示,在34例可解释结果的病例中,没有一例具有EGFR基因扩增。在表达EGFR蛋白的18例中有7例(39%)中,由于多体性7而导致的基因拷贝数增加,而在未表达EGFR蛋白的16例中有4例(25%)中发现了基因拷贝数增加(P = 0.3876)。 EGFR染色呈阳性的十个(56%)肿瘤表现出平衡的二体性7型分布,而一例具有7号单体性的肿瘤中则具有较强的EGFR表达(3+)。这些结果表明,通过基因扩增以外的其他机制,在一半以上的肛管鳞状细胞癌中EGFR过度表达。这些发现可能具有重要的治疗意义,因为基于EGFR的靶向疗法已显示出对其他恶性肿瘤的希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号